Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects ...

Exparel is Pacira’s flagship pain ... It is also indicated for regional analgesia in adults via an interscalene brachial ...

Pacira Pharmaceuticals’ bid to expand the use of its pain therapy Exparel has hit a major speed-bump after FDA advisers did not back an extended use as a nerve block after surgery. While the ...

EXPAREL is the only product indicated for local analgesia via infiltration in patients aged six years and older and regional analgesia via interscalene brachial plexus nerve block, sciatic nerve ...

US pharma Pacira hopes for a further expansion of the label for its nerve block Exparel covering surgical procedures throughout the body, after the FDA opted to expand its use to include shoulder ...

This new patent highlights our commitment to building a broad portfolio of intellectual property to protect our EXPAREL franchise by expanding its patent life into 2044,” said Frank D. Lee, chief ...

The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic ...

EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults ...

Four employees received stock options to purchase an aggregate of 19,800 shares of Pacira common stock and the four employees received restricted stock units for an aggregate of 23,600 shares of ...